Essays on Government Policy and Pharmaceutical Innovation
New drug therapies may deliver many social and economic benefits, but current levels of innovation across diseases may not be socially optimal. This dissertation investigates two mechanisms by which governments may influence pharmaceutical research and development (R&D) priorities: (1) public funding for life sciences research; and (2) prescription drug insurance, as in Medicare Part D. The author finds federal funding for life sciences research spurs non-federal investment in academic R&D as well as downstream drug development. Likewise, introduction of Medicare Part D increased both the number of drugs entering clinical trials and firm R&D expenditures for higher-Medicare-share drugs.
- Copyright: RAND Corporation
- Availability: Web-Only
- Pages: 109
- Document Number: RGSD-248
- Year: 2009
- Series: Dissertations
This document was submitted as a dissertation in June 2009 in partial fulfillment of the requirements of the doctoral degree in public policy analysis at the Pardee RAND Graduate School. The faculty committee that supervised and approved the dissertation consisted of Neeraj Sood (Chair), Greg Ridgeway, and Dana Goldman.
This report is part of the RAND Corporation dissertation series. PRGS dissertations are produced by graduate fellows of the Pardee RAND Graduate School, the world's leading producer of Ph.D.'s in policy analysis. The dissertations are supervised, reviewed, and approved by a PRGS faculty committee overseeing each dissertation.
Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.